Market Cap 1.59B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 95.13
Forward PE 37.30
Profit Margin -19.72%
Debt to Equity Ratio -1.73
Volume 1,457,500
Avg Vol 4,837,128
Day's Range N/A - N/A
Shares Out 210.74M
Stochastic %K 73%
Beta 0.91
Analysts Strong Sell
Price Target $20.60

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
ShortsHater
ShortsHater Dec. 25 at 12:59 AM
$BCRX shorted shares gone down finally which is a good sign it is bottomed. Now it will be a race to cover quicker before it goes higher faster
1 · Reply
Pharm_Hand
Pharm_Hand Dec. 24 at 7:11 PM
$BCRX Nope. Many CEOs in this space go on to bring ring their companies to greattnes. And then there's the Jon Stoenehouses of the world that don't do jack shit
0 · Reply
Terramin
Terramin Dec. 24 at 6:31 PM
$CAPR most of the small biotechs I follow are usually very difficult holds after approval because the sales takes a long time to ramp up. Some, like $BCRX spend years going nowhere even when the product sales increase because of limited market and bad management. Capricor has big sales and no competition from day 1, only manufacturing capacity holding them back. Traders like Sandeman and Mclim should take note. The management team is still unproven commercially but they have a partner to help with sales and distribution that already has a big footprint in the DMD space. Expanding label opportunities could happen within the first year after approval (Beckers DMD). There are certain bios like $ABVX that have compelling data, already have completed financing, and are no brainer holds. Capricor is now in those ranks.
2 · Reply
ShortsHater
ShortsHater Dec. 24 at 5:49 PM
$BCRX shorts will feel the pain like $OMER shorts some day
0 · Reply
ShortsHater
ShortsHater Dec. 24 at 5:39 PM
$BCRX will be a $50+ in 2030 or before, bold prediction
0 · Reply
yumkatel
yumkatel Dec. 24 at 5:18 PM
$BCRX fooking weak ass even won’t go up 5%
0 · Reply
thehivemindfund
thehivemindfund Dec. 24 at 5:07 PM
$OMER if you suspect a buyout, prepare for huge dip. fire sale on puts. this is a tiny market - smaller than $BCRX Orladeyo
0 · Reply
Vanderm98
Vanderm98 Dec. 24 at 4:43 PM
$BCRX GL!
0 · Reply
Pharm_Hand
Pharm_Hand Dec. 24 at 4:21 PM
$BCRX more weak sauce Jon. Don't youl get bored sprinkling this bs sauce all over your baby?
1 · Reply
jewell69
jewell69 Dec. 24 at 4:06 PM
$BCRX don't laugh it is more than a tank of gas profit. So easy, even a caveman can do it 12/24/2025 Sell Trade Details BCRX BIOCRYST PHARMACEUTICALS 400 $7.6573 $0.07 $3,062.85 12/23/2025 Buy Trade Details BCRX BIOCRYST PHARMACEUTICALS 400 $7.51 -$3,004.00
1 · Reply
Latest News on BCRX
BioCryst to Present at Upcoming Investor Conference

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

BioCryst to Present at Upcoming Investor Conference


BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 1:16 PM EDT - 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript


BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 2 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS


BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 29, 2025, 2:53 AM EDT - 3 months ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle


BioCryst Announces Departure of Dr. Helen Thackray

Aug 11, 2025, 7:00 AM EDT - 4 months ago

BioCryst Announces Departure of Dr. Helen Thackray


ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 6 months ago

ORLADEYO® (berotralstat) Approved in Colombia


BioCryst to Present at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Present at Upcoming Investor Conferences


BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 2:05 PM EDT - 8 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy


BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 8 months ago

BioCryst Appoints Steve Frank to Board of Directors


BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 8 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5


BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 10 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started


BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 26, 2025, 7:45 AM EST - 10 months ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up


BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 11 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal


ShortsHater
ShortsHater Dec. 25 at 12:59 AM
$BCRX shorted shares gone down finally which is a good sign it is bottomed. Now it will be a race to cover quicker before it goes higher faster
1 · Reply
Pharm_Hand
Pharm_Hand Dec. 24 at 7:11 PM
$BCRX Nope. Many CEOs in this space go on to bring ring their companies to greattnes. And then there's the Jon Stoenehouses of the world that don't do jack shit
0 · Reply
Terramin
Terramin Dec. 24 at 6:31 PM
$CAPR most of the small biotechs I follow are usually very difficult holds after approval because the sales takes a long time to ramp up. Some, like $BCRX spend years going nowhere even when the product sales increase because of limited market and bad management. Capricor has big sales and no competition from day 1, only manufacturing capacity holding them back. Traders like Sandeman and Mclim should take note. The management team is still unproven commercially but they have a partner to help with sales and distribution that already has a big footprint in the DMD space. Expanding label opportunities could happen within the first year after approval (Beckers DMD). There are certain bios like $ABVX that have compelling data, already have completed financing, and are no brainer holds. Capricor is now in those ranks.
2 · Reply
ShortsHater
ShortsHater Dec. 24 at 5:49 PM
$BCRX shorts will feel the pain like $OMER shorts some day
0 · Reply
ShortsHater
ShortsHater Dec. 24 at 5:39 PM
$BCRX will be a $50+ in 2030 or before, bold prediction
0 · Reply
yumkatel
yumkatel Dec. 24 at 5:18 PM
$BCRX fooking weak ass even won’t go up 5%
0 · Reply
thehivemindfund
thehivemindfund Dec. 24 at 5:07 PM
$OMER if you suspect a buyout, prepare for huge dip. fire sale on puts. this is a tiny market - smaller than $BCRX Orladeyo
0 · Reply
Vanderm98
Vanderm98 Dec. 24 at 4:43 PM
$BCRX GL!
0 · Reply
Pharm_Hand
Pharm_Hand Dec. 24 at 4:21 PM
$BCRX more weak sauce Jon. Don't youl get bored sprinkling this bs sauce all over your baby?
1 · Reply
jewell69
jewell69 Dec. 24 at 4:06 PM
$BCRX don't laugh it is more than a tank of gas profit. So easy, even a caveman can do it 12/24/2025 Sell Trade Details BCRX BIOCRYST PHARMACEUTICALS 400 $7.6573 $0.07 $3,062.85 12/23/2025 Buy Trade Details BCRX BIOCRYST PHARMACEUTICALS 400 $7.51 -$3,004.00
1 · Reply
yumkatel
yumkatel Dec. 24 at 3:50 PM
$BCRX I need 8 plus Santa
1 · Reply
ShortsHater
ShortsHater Dec. 24 at 3:28 PM
$BCRX got forgotten for long time. Hopefully things will change in 2026
0 · Reply
ShortsHater
ShortsHater Dec. 24 at 3:26 PM
$BCRX got FDA approval and no significant price increase whereas $OMER got FDA approval and stock price goes up 70%+
1 · Reply
CeloBob
CeloBob Dec. 24 at 2:29 PM
0 · Reply
2YrsEarly
2YrsEarly Dec. 24 at 1:58 AM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 24 at 1:28 AM
Enter: $BCRX Calls Strike Price: $8 Expiry Date: JAN 16 2026 Buy in Price: $0.30 - $0.32 Sell Price: $0.62 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
yumkatel
yumkatel Dec. 23 at 9:26 PM
$BCRX Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Why the fooker keep selling their shares?
2 · Reply
Paulzk
Paulzk Dec. 23 at 8:18 PM
$BCRX Food for thought from AI on gold A Triple Top in a stock chart is a bearish reversal pattern showing three peaks at roughly the same price level after an uptrend, signaling that buying momentum is fading and a downtrend is likely, confirmed when the price breaks below the support level (neckline) between the peaks. It's a key indicator for traders to anticipate a shift from bullish to bearish sentiment, suggesting sellers are overpowering buyers at that resistance.
0 · Reply
Paulzk
Paulzk Dec. 23 at 8:01 PM
$BCRX Yes perhaps a bull flag followed by a cup and handle. Now we just need to see a breakout to prove the chartists correct.
0 · Reply
Fergus20
Fergus20 Dec. 23 at 7:53 PM
$BCRX wow. An actual bull flag forming. We might actually see 8 soon.
0 · Reply
Paulzk
Paulzk Dec. 23 at 7:47 PM
$BCRX There are approximately 42.5 to 43 million borrowers with federal student loans in the U.S., with total outstanding balances around $1.6 to $1.7 trillion as of mid-to-late 2025, though the exact number of actively repaying loans varies, with millions in forbearance, in-school, or grace periods, alongside the 19.5 million in active repayment, notes Education Data Initiative. Key Figures (as of late 2024/2025): Total Borrowers: Around 42.5 - 43 million have federal student loans. Total Federal Balance: Approximately $1.66 trillion. Actively Repaying: About 19.5 million borrowers are actively making payments. In Forbearance: Around 9-10 million borrowers are in forbearance. In School: Roughly 6.1 million borrowers are still in school.
1 · Reply
Paulzk
Paulzk Dec. 23 at 7:44 PM
$BCRX The Trump administration will start garnishing the wages of student loan borrowers in default in early January, a spokesperson for the U.S. Department of Education confirmed to CNBC on Tuesday. More than 5 million student loan borrowers are currently in default, and that total could swell to roughly 10 million borrowers soon, the Education Department said earlier this year. https://www.cnbc.com/2025/12/23/student-loan-borrowers-wage-garnishment.html
0 · Reply